Vertex Pharmaceuticals, Inc. XNAS: VRTX

Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Name: Vertex Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Vertex Pharmaceuticals, Inc.
Rating: 1.964986125
Author: Trendlyne DVM scores

Momentum Trap

about

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

469.68 -14.47 (-2.99%)

29.57% Gain from 52W Low

2.1M

XNAS Volume

XNAS 08 Jan, 2026 4:30 PM (EST)

Board Meeting

The next board meeting for Vertex Pharma is on 12 Jan 2026 for the purpose of 44 Annual J.P. Morgan Healthcare Conference See details

Low Financial Strength

27.8 / 100

Mid Valuation

38.8 / 100

Technically Moderately Bullish

62.8 / 100

Momentum Trap These stocks have average financials but are currently seeing momentum. Investors should exercise caution in buying these stocks View Similar Embed DVM

496

1Yr Price target upside is 6%

25 analysts

Vertex Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

29.57% Gain from 52W Low

SWOT Analysis

Vertex Pharma Live Price Chart